我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

大剂量阿托伐他汀治疗冠心病并发高脂血症的有效性与安全性(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第2期
页码:
187-189
栏目:
临床研究
出版日期:
2008-03-20

文章信息/Info

Title:
Effectiveness and safety of high dose of Atorvasatin in treating hyperlipidemia in patients with coronary heart disease
作者:
张青;  贾春芳;  李艳芳
首都医科大学附属北京安贞医院十二病房，北京　１０００２９
Author(s):
ZHANG Qing;  JIA Chunfang;  LI Yanfang
Beijing Anzhen Hospitai Affiliated to Capital Medical University，Beijing 100029,China
关键词:
阿托伐他汀; 高脂血症; 冠状动脉疾病
Keywords:
atorvastatin; hyperlipidemia; coronary disease
分类号:
R972;R541.4
DOI:
-
文献标识码:
A
摘要:
目的 比较阿托伐他汀80 mg/d与阿托伐他汀20 mg/d在冠心病并发高脂血症患者中调脂的疗效与安全性。方法 将血脂未达标的84例冠心病患者随机分成两组。80 mg组：阿托伐他汀80 mg/d；20 mg组：阿托伐他汀20 mg/d。治疗前、治疗后4周、12周检查血清总胆固醇（TC）、低密度脂蛋白胆固醇（LDLC）、高密度脂蛋白胆固醇（HDLC）、三酰甘油（TG）、谷丙转氨酶（ALT）、肌酸磷酸激酶（CK）。结果 阿托伐他汀20 mg/d与80 mg/d均能显著降低TC（P<0.01）、LDLC（P<0.01），阿托伐他汀80 mg/d作用强于20 mg/d（P<0.05）。结论 阿托伐他汀80 mg/d与20 mg/d均能显著降低TC、LDLC水平，80 mg组明显优于20 mg组，两种剂量均有好的安全性。
Abstract:
AIM To evaluate the effectiveness and reliability of Atorvastatin in the treatment of hyperlipidemia. METHODS Eighty four cases with hyperlipidemia combined with coronary heart disease were randomized divided into two groups: Atorvastatin 80 mg/d in group A and Atorvastatin 20 mg/d in group B. The levels of TC, LDLC, HDLC, TG, ALT and CK in serum were examined before therapy, and 4 weeks and 12 weeks after therapy. RESULTS The levels of TC (P<0.01) and LDLC (P<0.01) were significantly decreased in both groups but the dosage of 80 mg/d achieved better effect than the dosage of 20 mg/d. CONCLUSION Both the dosages of Atorvastatin 80 mg/d and 20 mg/d are effective and reliable in the treatment of hyperlipidemia. The dosage of Atorvastatin 80mg/d has better effect than the dosage of Atorvastatin 20 mg/d.

参考文献/References

［1］ Expert pamel on detection,Evaluation,and Treatmet of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol educational program( NCEP ) epert panel on detecation, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)［J］. JAMA, 2001,285(19): 2486-2497.

［2］ EUROASPIRE I and II Group.Clinical reality of coronary prevention guidelines a comparison of EUROPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention Intervention of Reduce Events［J］. Lancer,2001,357(9261):995-1001.

［3］ Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:The MIRACL study a randomize contrallect trail［J］, JAMA,2001,285(13):1711-1718.

［4］ Baigent C, keech A, Kearrny PM,et al. Efficacy and safety of cholesterollowerring treatment :prospective metaanalysis of data from 90.056 participant 8 in 14 randomised trials of statins［J］. Lancet,2005, 366(9494):1267-1278.

［5］ Heart protection study collaborative group. MRC/BHF Heart protection study of cholesterol lowering with atorvastatin in 20536 high risk individuals :a randomized placebocontrolled trial［J］. Lancet,2002, 360(9326):7-22.

［6］ Roberts WC.Getting more people on statins［J］.Am J Cardiol,2002, 90(6): 683-685.

［7］ 张守林,孙鲁民,高素琴,等. 阿托伐他汀与辛伐他汀调脂疗效比较［J］.中国医药导刊,2002, 4(4): 284-286.

［8］ 王惠华,卓越,李开沪,等. 阿托伐他汀治疗老年人混合型高脂血症的疗效和安全性. 中国医药导刊,2002,4(4): 281-283.

备注/Memo

备注/Memo:
收稿日期：2007-01-29.作者简介：张青，副主任医师Email:jiachunfang2000@yahoo.com.cn
更新日期/Last Update: